|
1
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu
J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive
care versus placebo plus best supportive care in Asian patients
with previously treated metastatic colorectal cancer (CONCUR): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 16:619–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu J, Kim TW, Shen L, Sriuranpong V, Pan
H, Xu R, Guo W, Han SW, Liu T, Park YS, et al: Results of a
randomized, double-blind, placebo-controlled, Phase III trial of
trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with
previously treated metastatic colorectal cancer: The TERRA study. J
Clin Oncol. 36:350–358. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Collaborating Centre for Chronic
Conditions, . Chronic obstructive pulmonary disease: National
clinical guideline for management of chronic obstructive pulmonary
disease in adults in primary and secondary care. Thorax. 59 (Suppl
1):S1–S232. 2004.
|
|
6
|
Andrassy KM: Comments on KDIGO 2012
clinical practice guideline for the evaluation and management of
chronic kidney disease. Kidney Int. 84:622–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Martinelli E, Cascinu S,
Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner
B, et al: Regorafenib for patients with metastatic colorectal
cancer who progressed after standard therapy: Results of the large,
single-arm, open-label phase IIIb CONSIGN study. Oncologist.
24:185–192. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramaswamy A, Ostwal V, Pande N, Sharma A,
Patil S, Thippeswamy R, Ghadyalpatil N, Roy R, Peshwe H, Poladia B,
et al: Practice patterns and outcomes with the use of regorafenib
in metastatic colorectal cancer: Results from the Regorafenib in
metastatic colorectal cancer-an Indian Exploratory analysis study.
South Asian J Cancer. 8:22–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM,
Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM,
et al: Regorafenib dose-optimisation in patients with refractory
metastatic colorectal cancer (ReDOS): A randomised, multicentre,
open-label, phase 2 study. Lancet Oncol. 20:1070–1082. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New reponse evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Euro J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
11
|
Yoshino T, Komatsu Y, Yamada Y, Yamazaki
K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, et
al: Randomized phase III trial of regorafenib in metastatic
colorectal cancer: Analysis of the CORRECT Japanese and
non-Japanese subpopulations. Invest New Drugs. 33:740–750. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ricotta R, Verrioli A, Ghezzi S, Porcu L,
Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M,
et al: Radiological imaging markers predicting clinical outcome in
patients with metastatic colorectal carcinoma treated with
regorafenib: Post hoc analysis of the CORRECT phase III trial
(RadioCORRECT study). ESMO Open. 1:e0001112017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishino M, Cryer SK, Okajima Y, Sholl LM,
Hatabu H, Rabin MS, Jackman DM and Johnson BE: Tumoral cavitation
in patients with non-small-cell lung cancer treated with
antiangiogenic therapy using bevacizumab. Cancer Imaging.
12:225–235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boonsirikamchai P, Asran MA, Maru DM,
Vauthey JN, Kaur H, Kopetz S and Loyer EM: CT findings of response
and recurrence, independent of change in tumor size, in colorectal
liver metastasis treated with bevacizumab. AJR Am J Roentgenol.
197:W1060–W1066. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lim Y, Han SW, Yoon JH, Lee JM, Lee JM,
Paeng JC, Won JK, Kang GH, Jeong SY, Park KJ, et al: Clinical
implication of anti-angiogenic effect of regorafenib in metastatic
colorectal cancer. PLoS One. 10:e01450042015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chandler GN and Telling M: Lymphangitis
carcinomatosa. Br Med J. 2:639–641. 1952. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas A and Lenox R: Pulmonary
lymphangitic carcinomatosis as a primary manifestation of colon
cancer in a young adult. CMAJ. 179:338–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bruce DM, Heys SD and Eremin O:
Lymphangitis carcinomatosa: A literature review. J R Coll Surg
Edinb. 41:7–13. 1996.PubMed/NCBI
|
|
19
|
Cyran CC, Kazmierczak PM, Hirner H, Moser
M, Ingrisch M, Havla L, Michels A, Eschbach R, Schwarz B, Reiser
MF, et al: Regorafenib effects on human colon carcinoma xenografts
monitored by dynamic contrast-enhanced computed tomography with
immunohistochemical validation. PLoS One. 8:e760092013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilhelm SM, Dumas J, Adnane L, Lynch M,
Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY
73-4506): A new oral multikinase inhibitor of angiogenic, stromal
and oncogenic receptor tyrosine kinases with potent preclinical
antitumor activity. Int J Cancer. 129:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Y, Rajantie I, Pajusola K, Jeltsch M,
Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T and
Alitalo K: Vascular endothelial cell growth factor receptor
3-mediated activation of lymphatic endothelium is crucial for tumor
cell entry and spread via lymphatic vessels. Cancer Res.
65:4739–4746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimizu K, Kubo H, Yamaguchi K, Kawashima
K, Ueda Y, Matsuo K, Awane M, Shimahara Y, Takabayashi A, Yamaoka Y
and Satoh S: Suppression of VEGFR-3 signaling inhibits lymph node
metastasis in gastric cancer. Cancer Sci. 95:328–333. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bekaii-Saab T, Kim R, Kim TW, O'Connor JM,
Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K,
Yoshino T and Prager GW: Third- or later-line therapy for
metastatic colorectal cancer: Reviewing best practice. Clin
Colorectal Cancer. 18:e117–e129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schultheis B, Folprecht G, Kuhlmann J,
Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J,
Krauss J, et al: Regorafenib in combination with FOLFOX or FOLFIRI
as first- or second-line treatment of colorectal cancer: Results of
a multicenter, phase Ib study. Ann Oncol. 24:1560–1567. 2013.
View Article : Google Scholar : PubMed/NCBI
|
